Current trends in the development of histone deacetylase inhibitors: A review of recent patent applications

Florian Thaler

doi:10.4155/ppa.11.3

Current trends in the development of histone deacetylase inhibitors: A review of recent patent applications

Florian Thaler

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Histone deacetylases (HDACs) have become an important target for the treatment of cancer and other diseases. Currently, more than ten HDAC inhibitors have entered clinical studies and two of them have already reached the market. The hydroxamic acid derivative SAHA (also known as vorinostat or Zolinza®) and the cyclic depsipeptide FK228 (romidepsin or Istodax®) have gained approval from the US FDA for the treatment of cutaneous T-cell lymphoma. Nevertheless, there has been a continuous effort aimed at discovering a new generation of clinical candidates with improved pharmaceutical properties. This review provides a summary of the most recent patents published from mid-2009 to mid-2011.

Original language	English
Pages (from-to)	75-90
Number of pages	16
Journal	Pharmaceutical patent analyst
Volume	1
Issue number	1
DOIs	https://doi.org/10.4155/ppa.11.3
Publication status	Published - 2012

ASJC Scopus subject areas

Drug Discovery
Pharmaceutical Science

Access to Document

10.4155/ppa.11.3

Fingerprint Dive into the research topics of 'Current trends in the development of histone deacetylase inhibitors: A review of recent patent applications'. Together they form a unique fingerprint.

Cite this

@article{1f62a4f77892474b83413636eb5890d7,

title = "Current trends in the development of histone deacetylase inhibitors: A review of recent patent applications",

abstract = "Histone deacetylases (HDACs) have become an important target for the treatment of cancer and other diseases. Currently, more than ten HDAC inhibitors have entered clinical studies and two of them have already reached the market. The hydroxamic acid derivative SAHA (also known as vorinostat or Zolinza{\textregistered}) and the cyclic depsipeptide FK228 (romidepsin or Istodax{\textregistered}) have gained approval from the US FDA for the treatment of cutaneous T-cell lymphoma. Nevertheless, there has been a continuous effort aimed at discovering a new generation of clinical candidates with improved pharmaceutical properties. This review provides a summary of the most recent patents published from mid-2009 to mid-2011.",

author = "Florian Thaler",

year = "2012",

doi = "10.4155/ppa.11.3",

language = "English",

volume = "1",

pages = "75--90",

journal = "Pharmaceutical patent analyst",

issn = "2046-8962",

publisher = "Future Science",

number = "1",

}

TY - JOUR

T1 - Current trends in the development of histone deacetylase inhibitors

T2 - A review of recent patent applications

AU - Thaler, Florian

PY - 2012

Y1 - 2012

N2 - Histone deacetylases (HDACs) have become an important target for the treatment of cancer and other diseases. Currently, more than ten HDAC inhibitors have entered clinical studies and two of them have already reached the market. The hydroxamic acid derivative SAHA (also known as vorinostat or Zolinza®) and the cyclic depsipeptide FK228 (romidepsin or Istodax®) have gained approval from the US FDA for the treatment of cutaneous T-cell lymphoma. Nevertheless, there has been a continuous effort aimed at discovering a new generation of clinical candidates with improved pharmaceutical properties. This review provides a summary of the most recent patents published from mid-2009 to mid-2011.

AB - Histone deacetylases (HDACs) have become an important target for the treatment of cancer and other diseases. Currently, more than ten HDAC inhibitors have entered clinical studies and two of them have already reached the market. The hydroxamic acid derivative SAHA (also known as vorinostat or Zolinza®) and the cyclic depsipeptide FK228 (romidepsin or Istodax®) have gained approval from the US FDA for the treatment of cutaneous T-cell lymphoma. Nevertheless, there has been a continuous effort aimed at discovering a new generation of clinical candidates with improved pharmaceutical properties. This review provides a summary of the most recent patents published from mid-2009 to mid-2011.

UR - http://www.scopus.com/inward/record.url?scp=84877834926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877834926&partnerID=8YFLogxK

U2 - 10.4155/ppa.11.3

DO - 10.4155/ppa.11.3

M3 - Article

C2 - 24236715

AN - SCOPUS:84877834926

VL - 1

SP - 75

EP - 90

JO - Pharmaceutical patent analyst

JF - Pharmaceutical patent analyst

SN - 2046-8962

IS - 1

ER -